Real-World Patient-Reported Outcomes, Clinical Profile, and Treatment Patterns in a Subset of Patients with HR-Positive, HER2-Negative, Advanced Breast Cancer with Poor Prognostic Factors

2021 Year in Review - HER2-Negative Breast Cancer —January 21, 2022


Breast Cancer

Patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer who have disease-related poor prognostic factors are not well-documented. A real-world study was performed to describe patient demographics, disease characteristics, treatment patterns, and patient-reported outcomes in a subset of patients with HR-positive, HER2-negative, advanced breast cancer when cyclin-dependent kinase (CDK)4/6 inhibitors were introduced. The aim was to see how these factors influenced treatment decisions at the time of the survey, along with evaluating the demographics, illness features, treatment patterns, and patient-reported outcomes of these patients, with a focus on disease-related poor prognostic variables.

Real-world data came from a comprehensive, global survey of oncologists and their patients with HR-positive, HER2-negative, advanced breast cancer in 5 European Union countries and the United States. The data were gathered between March and June 2017, at the onset of the changing therapy landscape, when CDK4/6 inhibitors were becoming more widely used. Visceral metastases, liver metastases (a subtype of visceral metastases), progesterone receptor–negative status, and high tumor grade were all investigated as unfavorable prognostic variables.

In all, 2259 patients with HR-positive, HER2-negative, advanced breast cancer had records that could be used in this study.1 In 63% of patients, ≥1 adverse prognostic markers were present. The most common adverse prognostic marker was visceral metastases and the least common was progesterone receptor–negative status. There were different degrees of overlap between factors. With the presence of unfavorable prognostic indicators, particularly liver metastases, pain increased and performance status and activities of daily life decreased. There were no evident trends in patient-reported outcomes. As these drugs were being introduced to market, treatment with combined endocrine therapy plus CDK4/6 inhibitors was uncommon at that time.1

The need of administering efficient CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status. Future research could shed light on how the therapy environment for patients with poor prognostic characteristics has changed over time.


  1. Davie A, Cuyun Carter G, Rider A, et al. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study. ESMO Open. 2021;6:100226.
Related Articles
Breast Cancer Screening Among Women with Comorbidities: A Cross-Sectional Examination of Disparities from the Behavioral Risk Factor Surveillance System
Ashton Gatewood, MPH, BSN, RN, Mackenzie Enmeier, BS, Elise Stephenson, BA, Jordyn Austin, BS, Benjamin Greiner, DO, MPH, Micah Hartwell, PhD
June 2022 Vol 13, No 6
We found that people with co-occurring diagnoses including obesity, diabetes, hypertension, skin cancer, and arthritis completed breast cancer screening more often than those with no comorbidities. Conversely, individuals living with CVD, COPD, and depression were less likely to receive potentially lifesaving breast cancer screening, suggesting biases may be present in women with these diagnoses.
What AYAs with Breast Cancer and Their Providers Tell Us About Survivorship Needs
Heather Becker, PhD, Molly McAdam, MPH, Sharyn Malatok, MPA, Emily Croce, MSN, APRN, CPNP-PC, Eunju Choi, PhD, Elaine Gonzales, CN-BA, CHW, CHWI
April 2022 Vol 13, No 4
Sacituzumab Govitecan-hziy in the Treatment of HR-Positive Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
Last modified: January 21, 2022

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code